Analysis of influencing factors of postoperative effect after low-temperature plasma ablation
GUO Yu’na1 LI Xiaolin2 LIU Jingjie1 DOU Zhi1 YANG Liqiang1 PANG Haitao2▲
1.Department of Pain, Xuanwu Hospital, Capital Medical University, Beijing 100053, China;
2.Department of Anesthesiology, Dongzhimen Hospital (Tongzhou District), Beijing University of Chinese Medicine, Beijing 101121, China
Abstract：Objective To analyze the influencing factors of low-temperature plasma ablation in the treatment of postoperative herpes zoster neuralgia (PHN). Methods A total of 150 PHN patients admitted to the Department of Pain, Xuanwu Hospital of Capital Medical University from January 2016 to December 2018 were selected as the research objects, according to the postoperative effect, the patients were divided into test group (excellent postoperative effect, 102 cases) and control group (postoperative poor effect, 48 cases). All patients underwent low-temperature plasma ablation. The age, gender, preoperative visual analogue scale (VAS), course of disease, body mass index, smoking, hyperalgesia, diabetes, hypertension, prodromal symptoms, pain location were listed as independent variables, and a logistic regression model was established to screen out statistics and to learn the meaning of variables. Results There were statistically significant differences between the two groups in age, course of disease, preoperative VAS, hyperalgesia, and history of diabetes (P ＜ 0.05). Age (OR = 2.675, 95%CI: 2.296-4.992), preoperative VAS ≥ 7 points (OR = 1.112, 95%CI: 1.101-1.253), course of disease ≥ 1 year (OR = 2.201, 95%CI: 1.342-2.223), combined hyperalgesia (OR = 1.984, 95%CI: 1.426-2.376) and history of diabetes (OR = 2.569, 95%CI: 1.673-3.721) were risk factors of postoperative effect of PHN (P ＜ 0.05). Conclusion During the treatment process, it is necessary to focus on the elderly with diabetes, patients with long course of disease, preoperative hyperalgesia, and high VAS.
[1] 段苡文，郭书萍.带状疱疹后遗神经痛研究进展[J].中华老年多器官疾病杂志，2019，18（7）：552-556.
[2] Yawn BP. It is an exciting time in the study and management of shingles and postherpetic neuralgia （PHN） Introduction [J]. Popul Health Manag，2012，15（6）：381.
[3] Chen YT，Wang HH，Wang TJ，et al. Early application of low-level laser may reduce the incidence of postherpetic neuralgia （PHN） [J]. J Am Acad Dermatol，2016，75（3）：572-577.
[4] Bekara F，Chaput B，Teot L，et al. Coblation Therapy in the Management of Chronic Wounds [J]. Plast Reconstr Surg，2018，139（4）：1026e-1028e.
[5] Yang ZQ. Prevalence and control of hypertension among a community of elderly population [J]. BMC，2019，1（17）：176.
[6] Li H. The guidelines for prevention and control of overweight and obesity in Chinese adults [J]. Biomed Environ Sci，2019，1（12）：22-26.
[7] Jacoson L. The Diognosis of Pain [J]. BMC Anesthesiol，2018，3（2）：26.
[8] Ozawa A，Haruki Y，Iwashita K，et al. Follow-up of clinical efficacy of iontophoresis therapy for postherpetic neuralgia （PHN） [J]. J Dermatol，1999，26（1）：1-10.
[9] Rohof OJ. Caudal Epidural of Pulsed Radiofrequency in Post Herpetic Neuralgia （PHN）；Report of Three Cases [J]. Anesth Pain Med，2014，4（3）：e16369.
[10] Gelb LD. Reducing the incidence and severity of herpes zoster and PHN with zoster vaccination [J]. J Am Osteopath Assoc，2009，109（6 Suppl 2）：S18-S21.
[11] Abraham A. Post herpetic neuralgia （PHN） [J]. Indian J Dermatol Venereol Leprol，2001，67（1）：30.
[12] Johnson RW，Bouhassira D，Kassianos G，et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life [J]. BMC Med，2019，8：37.
[13] Malec-Milewska M，Sekowska A，Koleda I，et al. Sympathetic nerve blocks for the management of postherpetic neuralgia-19 years of pain clinic experience [J]. Anaesthesiol Intensive Ther，2019，46（4）：255-261.
[14] Nalamachu S，Morley-Forster P. Diagnosing and managing postherpetic neuralgia [J]. Drugs Aging，2018，29（11）：863-869.
[15] Petersen KL，Rice FL，Farhadi M，et al. Natural history of cutaneous innervation following herpes zoster [J]. Pain，2019，150（1）：75-82.
[16] 卢之和.糖尿病患者饮食护理[J].中国老年学杂志，2019（34）：80.
[17] Dworkin RH，Panarites CJ，Armstrong EP，et al. Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations? [J]. Pain，2018，153（4）：869-875.
[18] Smith HS，Sang CN. The evolving nature of neuropathic pain：individualizing treatment [J]. Eur J Pain，2018，6（Suppl B）：13-18.
[19] Onal A，Delen Y，Ulker S，et al. Agmatine attenuates neuropathic pain in rats：possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum [J]. Life Sci，2003，73（4）：413-428.
[20] Cardose-Cruz H，Lima D. Impaired spatial memory performance in a rat model of neuropathic pain is associated with reduced hippocampus-prefrontal cortex connectivity [J]. J Neurosci，2013，33：2465-2480.
2021, Vol. 18 
京公网安备 11010502046598号